Drug Profile

LIS 1

Alternative Names: LIS1

Latest Information Update: 01 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xenothera
Class Antineoplastics; Polyclonal antibodies
Mechanism of Action Immunosuppressants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Transplant rejection
New Molecular Entity Yes

Highest Development Phases

Phase II Graft-versus-host disease; Renal transplant rejection

Most Recent Events

11 Jul 2022 LIS 1 receives Orphan Drug status for Transplant rejection in Europe
11 Jul 2022 Xenothera plans a phase II/III trial for Renal transplant rejection in Europe and USA in 2023
27 Jun 2022 The Committee for Orphan Medicinal Products (COMP) adopts a positive opinion for orphan drug designation for LIS 1 for Transplant rejection in Europe

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com